These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 17419952)

  • 41. Identification of ANKRD11 as a p53 coactivator.
    Neilsen PM; Cheney KM; Li CW; Chen JD; Cawrse JE; Schulz RB; Powell JA; Kumar R; Callen DF
    J Cell Sci; 2008 Nov; 121(Pt 21):3541-52. PubMed ID: 18840648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current strategies to target p53 in cancer.
    Chen F; Wang W; El-Deiry WS
    Biochem Pharmacol; 2010 Sep; 80(5):724-30. PubMed ID: 20450892
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors.
    Romeo S; Debiec-Rychter M; Van Glabbeke M; Van Paassen H; Comite P; Van Eijk R; Oosting J; Verweij J; Terrier P; Schneider U; Sciot R; Blay JY; Hogendoorn PC;
    Clin Cancer Res; 2009 Jun; 15(12):4191-8. PubMed ID: 19509155
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transcription regulation by mutant p53.
    Weisz L; Oren M; Rotter V
    Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
    Bullock AN; Henckel J; Fersht AR
    Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Myc oncoprotein as a therapeutic target for human cancer.
    Vita M; Henriksson M
    Semin Cancer Biol; 2006 Aug; 16(4):318-30. PubMed ID: 16934487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy.
    Resnick-Silverman L; Manfredi JJ
    J Cell Biochem; 2006 Oct; 99(3):679-89. PubMed ID: 16676359
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene therapy: a molecular approach to cancer treatment.
    Anklesaria P
    Curr Opin Mol Ther; 2000 Aug; 2(4):426-32. PubMed ID: 11249773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. To die or not to die: how does p53 decide?
    Slee EA; O'Connor DJ; Lu X
    Oncogene; 2004 Apr; 23(16):2809-18. PubMed ID: 15077144
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells.
    Choi MS; Oh JH; Kim SM; Jung HY; Yoo HS; Lee YM; Moon DC; Han SB; Hong JT
    Int J Oncol; 2009 May; 34(5):1221-30. PubMed ID: 19360335
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells.
    Choi SH; Jin SE; Lee MK; Lim SJ; Park JS; Kim BG; Ahn WS; Kim CK
    Eur J Pharm Biopharm; 2008 Mar; 68(3):545-54. PubMed ID: 17881199
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficient therapeutic gene delivery after systemic administration of a novel polyethylenimine/DNA vector in an orthotopic bladder cancer model.
    Sweeney P; Karashima T; Ishikura H; Wiehle S; Yamashita M; Benedict WF; Cristiano RJ; Dinney CP
    Cancer Res; 2003 Jul; 63(14):4017-20. PubMed ID: 12874000
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Life and death by p53.
    Elledge RM; Lee WH
    Bioessays; 1995 Nov; 17(11):923-30. PubMed ID: 8526886
    [TBL] [Abstract][Full Text] [Related]  

  • 54. p53 tumor-suppressor gene: clues to molecular carcinogenesis.
    Wang XW; Harris CC
    J Cell Physiol; 1997 Nov; 173(2):247-55. PubMed ID: 9365531
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy.
    Wang XW; Harris CC
    Cancer Surv; 1996; 28():169-96. PubMed ID: 8977035
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A recombinant cell-permeable p53 fusion protein is selectively stabilized under hypoxia and inhibits tumor cell growth.
    Yu Z; Wu J; Wu S; Jia P; Tong Y; Wu X; Wang Y
    Cancer Lett; 2009 Jun; 279(1):101-7. PubMed ID: 19232460
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Tumor suppressor p53 gene: a potential target for cancer therapy?].
    Soussi T
    Bull Cancer; 1997 Jul; 84(7):753-6. PubMed ID: 9339203
    [No Abstract]   [Full Text] [Related]  

  • 58. Living with p53, dying of p53.
    Aylon Y; Oren M
    Cell; 2007 Aug; 130(4):597-600. PubMed ID: 17719538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-viral gene delivery for p53.
    Pirollo KF; Xu L; Chang EH
    Curr Opin Mol Ther; 2000 Apr; 2(2):168-75. PubMed ID: 11249638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.